Meanwhile, there is a variety of BCR:ABL1 TKIs used for CML, namely, the second generation nilotinib, dasatinib, bosutinib, third generation ponatinib, and the novel STAMP-inhibitor (specifically targeting the BCR:ABL1 myristoyl pocket) asciminib (Schoepfer et al., 2018; Luciano et al., 2020), which all differ in the spectrum of targeted kinases and side effects (Kaehler and Cascorbi, 2023) (Table 1). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.